Clinical Implications of Performance Enhancing Drugs upon Cardiovascular Health

Angell, Peter J. and Schumacher, Yorck O (2016) Clinical Implications of Performance Enhancing Drugs upon Cardiovascular Health. In: IOc Manual of Sports Cardiology. Wiley Blackwell, pp. 468-474. ISBN ISBN: 9781119046868

Full text not available from this repository. (Request a copy)


Despite increased control on the use of performance-enhancing drugs both ‘in’ and ‘out’ of competition, as well as increasing punishments for those found contravening the rules, there remains those athletes willing to risk using substances to improve their performance and/or aid their recovery (Yesalis and Bahrke, 2002). The World Anti-Doping Agency (WADA) strictly regulates the use of pharmaceutical products in competitive sport. WADA produces and regularly updates the World Anti-Doping Code that includes a prohibited drug list. This list dictates what is and is not acceptable, from a doping perspective, within sport (Table 1). In addition to using these restrictions to promote the Olympic ideal of free and fair competition, they are also in place for the protection of athletes and to help prevent the negative health consequences associated with the use of many substances on the list. This chapter shall therefore examine impact of performance enhancing drugs from a range of categories on cardiovascular health.

Item Type: Book Section
Faculty / Department: Faculty of Science > School of Health Sciences
Depositing User: Peter Angell
Date Deposited: 25 Jul 2018 13:35
Last Modified: 25 Jul 2018 13:35

Actions (login required)

View Item View Item